Biohaven Ltd 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Biohaven Ltd 's ROA in the second quarter of 2026?
Biohaven Ltd recorded a cumulative net loss of $-587 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -138.27%.

However, within the Healthcare sector 795 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4372, from total ROA ranking in the first quarter of 2026 at 5120.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-32.64 %	1.63 %	-26.61 %	-19.86 %	-5.53 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-587	-648	-739	-780	-767
Return On Assets (TTM)	-138.27 %	-138 %	-158.04 %	-153.44 %	-143.7 %
BHVN's Total Ranking	# 4372	# 5120	# 4521	# 4585	# 4695
Total Assets (TTM) in million	371	466	451	409	550
Seq. Total Assets Change	-20.51 %	3.31 %	10.35 %	-25.67 %	19.93 %
Seq. Net Income Change	-	-	-	-	-

BHVN's 5 Years Annual ROA >> Back to BHVN Management Effectiveness >> Compare BHVN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 374
Sector	# 796
Overall	# 4334

Return On Assets Statistics
High	Average	Low
-63.26 %	-123.69 %	-164.01 %
(Mar 31 2022)		(Mar 31 2025)

News about Biohaven Ltd Return on Assets ROA

Legal Turmoil in Biopharmaceuticals Analyzing the Class Action Against Biohaven Ltd.

: As bio-pharmaceutical companies navigate complex regulatory landscapes and the unpredictable waters of the securities market, instances of legal action against them remain significant touchpoints for industry stakeholders. This article delves into the recent class action lawsuit filed against Biohaven Ltd. by the Pomerantz Law Firm and the potential implications for investors and the wider biopharmaceutical industry. Specifically, we will explore the context of the lawsuit, the alleged violations of securities laws, and the broader ramifications for investor trust and corporate governance in biohealth firms. In the fast-paced world of pharmaceutical development and investment, maintaining investor confidence is paramount. Recent events surrounding Biohaven Ltd. (NYSE: BHVN) have thrown a stark spotlight on the legal and ethical obligations of publicly traded companies. Pomerantz LLP has announced the filing of a class action lawsuit against Biohaven and certain corporate officers, citing violations of federal securities laws. This article analyzes the implications of this lawsuit for the firm, its investors, and the biopharmaceutical sector as a whole.

Navigating Troubled Waters Biohaven Ltd. Faces Class Action Amid Financial Struggles

The pharmaceutical industry is frequently characterized by its volatility and the complexities surrounding financial performance and regulatory compliance. A recent class action lawsuit filed against Biohaven Ltd. highlights the potential risks faced by companies in this sector as they attempt to navigate the delicate balance between innovation, market expectations, and financial accountability.On September 6, 2025, the Pomerantz Law Firm announced a class action lawsuit against Biohaven Ltd. and certain officers, lodged in the United States District Court for the District of Connecticut. The lawsuit, d under docket number 25-cv-01120, involves a class representing all individuals and entities, excluding the defendants, that purchased or acquired Biohaven securities during the period from March 24, 2023, to May 14, 2025. The plaintiffs seek to recover damages stemming from alleged violations of federal securities laws, specifically targeting Section 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5.

Financial Statements
Biohaven Ltd 's Assets	$ 371 million	BHVN's Balance sheet
Biohaven Ltd 's Income	$ -137 million	Quarterly BHVN's Income Statement
BHVN's Income by Division		See BHVN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-26.61 %	-15.36 %	9.82 %	-38.57 %	65.79 %
Total Assets in million	451	615	727	662	1,077
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-739	-846	-408	-570	-848
Annual Return On Assets	-163.66 %	-137.61 %	-56.16 %	-86.17 %	-78.76 %

BHVN's 5 Years Annual ROA >> Back to BHVN Management Effectiveness >> Compare BHVN ROA to its Competitors

More Return On Assets Ratios
BHVN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BHVN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BHVN's Competitors
Subscribers only: Roa for Biohaven Ltd 's Suppliers
Subscribers only: Return On Assets for BHVN's Customers

You may also want to know
BHVN's Roi	BHVN's Inventory Turnover Ratio	BHVN's Growth Rates	BHVN's Dividend Comparisons
	BHVN's Profitability Ratios	BHVN's Asset Turnover Ratio	BHVN's Dividend Growth
BHVN's Roe	BHVN's Valuation Ratios	BHVN's Financial Strength Ratios	BHVN's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-13T05:53:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.